We demonstrate that NPM-ALK inhibition by ALK specific tyrosine kinase inhibitors (TKIs) or degradation by the newly developed PROTAC TL13-112 induced the upregulation of CD45, specifically the CD45RO isoform that is mainly expressed in ALK+ ALCL cell lines. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.